Wall Street analysts forecast that Citius Pharmaceuticals Inc (NASDAQ:CTXR) will post earnings per share (EPS) of ($0.06) for the current quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Citius Pharmaceuticals’ earnings. Citius Pharmaceuticals posted earnings of ($0.19) per share during the same quarter last year, which would indicate a positive year over year growth rate of 68.4%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 13th.

According to Zacks, analysts expect that Citius Pharmaceuticals will report full-year earnings of ($0.56) per share for the current fiscal year. For the next year, analysts expect that the business will post earnings of $0.06 per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that cover Citius Pharmaceuticals.

Citius Pharmaceuticals (NASDAQ:CTXR) last announced its earnings results on Wednesday, May 15th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20).

Separately, Zacks Investment Research cut Hudson Technologies from a “hold” rating to a “sell” rating in a report on Monday, April 1st.

NASDAQ:CTXR traded up $0.03 during mid-day trading on Thursday, reaching $1.05. The stock had a trading volume of 1,118 shares, compared to its average volume of 96,243. The stock has a market cap of $23.20 million, a P/E ratio of -0.90 and a beta of 0.51. Citius Pharmaceuticals has a 1-year low of $0.86 and a 1-year high of $3.15. The business has a 50 day simple moving average of $1.07.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

Featured Article: What is the Quick Ratio?

Get a free copy of the Zacks research report on Citius Pharmaceuticals (CTXR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.